GSK's $124/Share Tender Offer for Nuvalent Clears HSR Antitrust Review
NUVL sits 74% above its 52-week low of $71.13.
Summary
GSK's $124 per share all-cash tender offer for Nuvalent has cleared U.S. antitrust review, satisfying a key condition and paving the way for the deal to close.
Key Events · M&A and Partnerships · NUVL
-
HSR Antitrust Clearance Obtained
The waiting period under the Hart-Scott-Rodino Act expired on July 9, 2026, satisfying the HSR Condition to the Offer and removing the last major regulatory obstacle to the acquisition.
-
Tender Offer Terms Unchanged
GSK continues to offer $124.00 per share in cash for all outstanding Class A and Class B common stock of Nuvalent, representing a total equity value of approximately $10.6 billion.
-
Deal Timeline Accelerates
With antitrust clearance secured, the tender offer can now proceed to closing, which is expected to occur promptly following the satisfaction of remaining customary conditions.
-
Prior Disclosure Context
This amendment follows the initial tender offer launch on June 24, 2026, and a previous amendment on June 24, 2026. The HSR clearance was the primary outstanding regulatory condition.
Analysis · NUVL · Life Sciences
With the HSR waiting period now expired, the last major regulatory hurdle before the tender offer can close has been removed. Antitrust clearance is secured, clearing the path to completion, and the deal is expected to close promptly. This milestone confirms that no U.S. antitrust issues will delay or block the $10.6 billion acquisition.
At the time of this filing, NUVL was trading at $123.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.8B. The 52-week trading range was $71.13 to $123.86. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.